News

The company has announced positive OS results from the phase III randomised, double-blinded and multi-centre trial of Tagrisso in previously-untreated patients with locally-advanced or metastatic non-small cell lung

The updated preliminary Phase 3 clinical data will serve as the basis for the anticipated initiation of the Company’s BLA submission in 4Q 2019 “After two very positive

The FDA indicated that efficacy data from an additional clinical trial will be needed to support a resubmission. Kala continues to enroll patients in its ongoing STRIDE 3

The deal also includes an additional payment of $360m (£296.2m) based on achievement of pre-defined development milestones. The total investment in BlueRock is valued at around $1bn (£823m),

Vesselon will use Imagent to create novel therapeutic complexes in four classes of cancer drugs: cytokines, oncolytic viruses, monoclonal antibodies, and nucleic acid constructs. Vesselon incorporates Imagent into

Results from the trial showed a statistically-significant and clinically-meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) with Lynparza vs. enzalutamide or abiraterone in men with

As per terms of the merger deal, Cambrex shareholders will secure $60 (£49.3) in cash for each share of Cambrex common stock, representing a 47.1% premium to its

The agreements between GSK and Sabin in this regard are for advancing the development of the prophylactic candidate Ebola vaccines against the Ebola Zaire, Ebola Sudan and the

Dravet syndrome is a severe and progressive genetic epilepsy, characterized by frequent, prolonged and refractory seizures beginning within the first year of life. The effects of the disease